The data, to feature in a press conference at SSW this morning, builds on the idea that different forms of lutein react differently in the body.
It features Kemin's FloraGLO version of lutein and DSM's Actilease technology.
Kemin emphasised the importance of clinical backing to give a form of brand equity insurance.
"Lutein ingredient manufacturers use different processes to enrobe the lutein in order for it to be released into the body," Kemin said, noting their effect on bioavailability.
Lutein is typically quantified as macular pigment optical density (MPOD). Kemin suggested MPOD had the potential to become a validated biomarker for visual function and the risk for eye disease.
"Awareness of MPOD and the technology used for its measurement are growing among eye care practitioners and consumers," Kemin said.
"It is important for manufacturers to deliver on their promised health benefits on product labeling and formulate with a quality lutein ingredient that can assure delivery to beneficial sites of action,” said Heather Richardson, FloraGLO product manager for Kemin Health.
“The quality of a supplement brand and its ingredients, such as lutein and zeaxanthin, is critical as doctors are embracing new technology to measure and monitor MPOD levels in their patients.”